The company's first-generation product, LODER™, has shown promising results in a Phase 2 clinical trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback